Drugs / HB-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05553639 | May 2023 → Apr 2024 | metastatic prostate carcinoma | Hookipa Biotech GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05553639 ↗ |
| Route | Intravenous | “administered intravenously every 3 weeks (Q3W) for the first 5 doses and every 6 weeks (Q6W) from the fifth dose and onward” NCT05553639 ↗ |